Rutgers Cancer Institute | Strategic Alliance Partners

From radiopharmaceuticals to hypofractionated radiation therapy, one expert explained the current landscape of radiation treatments for prostate cancer.

One expert explains how bispecific antibodies are a ‘targeted and effective’ option for patients with multiple myeloma.